OnKure Therapeutics, Inc. (OKUR) shareholders
Close on Nov 17, 2026Market cap $104.48MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Access Industries Holdings LLC Joint filing with AI Biotechnology LLC (19.99%), Access Industries Management, LLC (19.99%) and 1 more | 9,091,532 | 19.99% | 13D (active) | Mar 31, 2026 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more | 4,038,715 | 9.90% | 13G (passive) | Mar 31, 2026 |
| Anders Hove Joint filing with Acorn Bioventures 2, L.P. (5.00%), Acorn Capital Advisors GP 2, LLC (5.00%) | 3,924,037 | 9.50% | 13G (passive) | Mar 27, 2026 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (8.00%), Bvf Inc/Il (8.00%) and 1 more | 3,235,778 | 8.00% | 13G (passive) amendment | Jun 30, 2026 |
| Kevin Tang Joint filing with Tang Capital Partners, LP (8.80%), Tang Capital Management, LLC (8.80%) | 2,946,260 | 8.80% | 13G (passive) | Sep 26, 2024 |
| Coastlands Capital GP LLC Joint filing with Coastlands Capital LP (6.67%), Coastlands Capital Partners LP (6.67%) and 2 more | 2,700,000 | 6.67% | 13G (passive) | Oct 1, 2026 |
| StepStone VC MI-G GP, LLC Joint filing with StepStone Group LP (6.60%), StepStone Master G, L.P. (6.60%) | 2,660,612 | 6.60% | 13G (passive) | Mar 31, 2026 |
| Daniel Schneeberger Joint filing with ADAR1 Capital Management, LLC (5.50%) | 2,238,684 | 5.50% | 13G (passive) amendment | Jun 30, 2026 |
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (5.30%), Lampert Mark N (5.30%) | 2,134,908 | 5.30% | 13G (passive) | May 19, 2026 |
| ADAR1 Capital Management, LLC Joint filing with Daniel Schneeberger (7.90%), ADAR1 Capital Management GP, LLC (6.20%) | 1,014,158 | 7.90% | 13G (passive) | Dec 31, 2025 |
| Shay Capital Holdings LLC Joint filing with Shay Capital LLC (6.30%) | 810,214 | 6.30% | 13G (passive) | May 15, 2025 |
| Prosight Partners, LLC Joint filing with Prosight Management, LP (5.80%), W. Lawrence Hawkins (5.80%) | 745,649 | 5.80% | 13G (passive) | Nov 24, 2025 |
| CF Group Management, Inc. Joint filing with Cantor Fitzgerald Securities (5.20%), Cantor Fitzgerald & Co. (5.20%) and 1 more | 669,539 | 5.20% | 13G (passive) | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OKUR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 3,998,333 | 9.87% | $18.23M | – | 0.16% |
| Bvf Inc/Il | 3,235,778 | 7.99% | $14.76M | +1,256,806 | 0.38% |
| Acorn Capital Advisors, LLC | 2,839,674 | 7.01% | $12.95M | – | 3.53% |
| StepStone Group LP | 2,660,612 | 6.57% | $12.13M | – | 0.56% |
| ADAR1 Capital Management, LLC | 2,238,684 | 5.53% | $10.21M | −196,257 | 0.47% |
| Vivo Capital, LLC | 1,927,710 | 4.76% | $8.79M | – | 0.80% |
| Vestal Point Capital, LP | 1,825,699 | 4.51% | $8.33M | −14,120 | 0.19% |
| BlackRock, Inc. | 1,499,845 | 3.70% | $6.84M | +1,450,258 | 0.00% |
| Trails Edge Capital Partners, LP | 1,438,456 | 3.55% | $6.56M | New | 1.04% |
| Vanguard Capital Management LLC | 1,437,039 | 3.55% | $6.55M | +854,562 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 1,204,819 | 2.98% | $5.49M | – | 0.01% |
| Citadel Advisors LLC | 1,187,047 | 2.93% | $5.41M | +1,149,460 | 0.00% |
| Sio Capital Management, LLC | 1,078,965 | 2.66% | $4.92M | – | 0.81% |
| Prosight Management, LP | 978,992 | 2.42% | $4.46M | −1,175,389 | 0.77% |
| Logos Global Management LP | 963,855 | 2.38% | $4.40M | New | 0.19% |
| Geode Capital Management, LLC | 724,438 | 1.79% | $3.30M | +625,688 | 0.00% |
| NEA Management Company, LLC | 478,548 | 1.18% | $2.18M | – | 0.14% |
| State Street Corp | 463,662 | 1.14% | $2.11M | +450,200 | 0.00% |
| Ensign Peak Advisors, Inc | 431,631 | 1.07% | $1.97M | New | 0.00% |
| Renaissance Technologies LLC | 358,738 | 0.89% | $1.64M | −18,512 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 75 | 35M | 86.3% | 32 / 21 | 9 / 8 | 11M | 4M |
| Q1 2026 | 51 | 28M | 68.0% | 18 / 12 | 14 / 9 | 20M | 2M |
| Q4 2025 | 44 | 11M | 27.4% | 8 / 9 | 16 / 6 | 3M | 2M |
| Q3 2025 | 42 | 10M | 25.2% | 1 / 15 | 13 / 8 | 0M | 1M |
| Q2 2025 | 49 | 11M | 26.6% | 8 / 16 | 13 / 6 | 4M | 5M |
| Q1 2025 | 47 | 12M | 29.5% | 4 / 15 | 13 / 8 | 1M | 1M |
| Q4 2024 | 51 | 12M | 29.2% | 20 / 20 | 10 / 19 | 10M | 1M |
| Q3 2024 | 51 | 3M | 7.1% | 7 / 16 | 14 / 21 | 0M | 0M |
| Q2 2024 | 66 | 3M | 6.9% | 21 / 14 | 21 / 17 | 0M | 0M |
| Q1 2024 | 62 | 3M | 6.9% | 12 / 14 | 19 / 18 | 0M | 0M |
| Q4 2023 | 68 | 3M | 6.3% | 27 / 17 | 16 / 17 | 1M | 1M |
| Q3 2023 | 58 | 3M | 6.8% | 10 / 22 | 13 / 4 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
49 funds held OKUR in Q2 2026, 86% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of OKUR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,109,823 | 2.74% | $5.06M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 483,134 | 1.19% | $2.20M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 302,423 | 0.75% | $1.38M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 285,510 | 0.71% | $1.09M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 193,829 | 0.48% | $883.86K | 0.01% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 79,084 | 0.20% | $360.62K | 0.02% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 63,640 | 0.16% | $243.10K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 41,652 | 0.10% | $189.93K | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Value Index Fund | 36,563 | 0.09% | $166.73K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 36,530 | 0.09% | $153.43K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 35,402 | 0.09% | $135.24K | 0.00% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 34,000 | 0.08% | $155.04K | 0.10% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 32,426 | 0.08% | $123.87K | 0.00% | Jul 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 22,417 | 0.06% | $102.22K | 0.00% | Jun 30, 2026 |
| LVIP State Street Small-Cap Index Fund | 20,500 | 0.05% | $93.48K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nicholas A. Saccomano | President and CEO, Director | 11,160 | 0.03% | Sep 23, 2026 |
| Jason A. Leverone | Chief Financial Officer | 18,500 | 0.05% | Sep 23, 2026 |
| Dylan Hartley | Chief Scientific Officer | – | – | Aug 11, 2026 |
| Samuel Agresta | Chief Medical Officer | – | – | Aug 11, 2026 |
| Isaac Manke | Director | 20,583 | 0.05% | Aug 13, 2026 |
| Andrew John Phillips | Director | – | – | Aug 11, 2026 |
| Michael G. Grey | Director | 494,762 | 1.22% | Aug 11, 2026 |
| R. Michael Carruthers | Director | 874 | 0.00% | Aug 11, 2026 |
| Liam Ratcliffe | Director | – | – | Aug 11, 2026 |
| Valerie Malyvanh Jansen | Director | – | – | Aug 11, 2026 |
| Edward T. Mathers | Director | 15,310 | 0.04% | Aug 11, 2026 |
| Access Industries Management, Llc | 10% owner | 3,998,332 | 9.87% | Apr 7, 2026 |
| Biotechnology LLC AI | 10% owner | – | – | Apr 7, 2026 |
| Industries Holdings LLC Access | 10% owner | – | – | Apr 7, 2026 |
| Len Blavatnik | 10% owner | – | – | Apr 7, 2026 |
| Acorn Bioventures 2, L.P. | 10% owner | – | – | May 27, 2025 |
| Acorn Capital Advisors GP 2, LLC | 10% owner | 1,129,730 | 2.79% | May 27, 2025 |
| Anders D. Hove | 10% owner | – | – | May 19, 2025 |
| Private Healthcare Fund III LP Cormorant | – | 0 | – | May 19, 2025 |
| Cormorant Global Healthcare Master Fund, LP | – | 1,813,439 | 4.48% | May 19, 2025 |
| Private Healthcare Fund V. LP Cormorant | – | – | – | May 19, 2025 |
| Private Healthcare Fund IV LP Cormorant | – | – | – | May 19, 2025 |
| Acorn Capital Advisors Gp, Llc | 10% owner | 4,279,348 | 10.57% | May 19, 2025 |
| Acorn Bioventures, L.P. | 10% owner | – | – | May 19, 2025 |
| Bihua Chen | – | – | – | May 19, 2025 |
| Cormorant Asset Management, LP | – | – | – | May 19, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Nicholas A. Saccomano President and CEO, Director | Sep 21, 2026 | Sale | −87 | $2.97 | $258 | 11,160 |
| Jason A. Leverone Chief Financial Officer | Sep 21, 2026 | Sale | −302 | $2.97 | $897 | 18,500 |
| Nicholas A. Saccomano President and CEO, Director | Jun 22, 2026 | Sale | −86 | $4.40 | $378 | 11,247 |
| Jason A. Leverone Chief Financial Officer | Jun 22, 2026 | Sale | −303 | $4.40 | $1.33K | 18,802 |
| Jason A. Leverone Chief Financial Officer | Mar 23, 2026 | Sale | −301 | $4.16 | $1.25K | 16,000 |
| Nicholas A. Saccomano President and CEO, Director | Mar 23, 2026 | Sale | −86 | $4.16 | $358 | 7,333 |
| Isaac Manke Director | Dec 31, 2025 | Award | +5,258 | – | – | 20,583 |
| Edward T. Mathers Director | Dec 31, 2025 | Award | +3,911 | – | – | 15,310 |
| Nicholas A. Saccomano President and CEO, Director | Dec 22, 2025 | Sale | −87 | $2.97 | $258 | 7,419 |
| Jason A. Leverone Chief Financial Officer | Dec 22, 2025 | Sale | −302 | $2.97 | $897 | 16,301 |
| Isaac Manke Director | Sep 30, 2025 | Award | +5,545 | – | – | 15,325 |
| Edward T. Mathers Director | Sep 30, 2025 | Award | +4,125 | – | – | 11,399 |
| Nicholas A. Saccomano President and CEO, Director | Sep 22, 2025 | Sale | −88 | $2.62 | $231 | 3,506 |
| Jason A. Leverone Chief Financial Officer | Sep 22, 2025 | Sale | −303 | $2.62 | $794 | 12,603 |
| Edward T. Mathers Director | Jun 30, 2025 | Award | +4,694 | – | – | 7,274 |
| Isaac Manke Director | Jun 30, 2025 | Award | +6,311 | – | – | 9,780 |
| Nicholas A. Saccomano President and CEO, Director | Jun 23, 2025 | Sale | −88 | $2.38 | $209 | 3,594 |
| Jason A. Leverone Chief Financial Officer | Jun 23, 2025 | Sale | −303 | $2.38 | $721 | 12,906 |
| Acorn Capital Advisors Gp, Llc 10% owner | May 15, 2025 | Buy | +270,270 | $1.85 | $500.00K | 1,709,944 |
| Acorn Capital Advisors Gp, Llc 10% owner | May 15, 2025 | Buy | +1,129,730 | $1.85 | $2.09M | 1,129,730 |
| Private Healthcare Fund III LP Cormorant – | May 15, 2025 | Sale | −1,813,439 | $1.85 | $3.35M | 0 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | May 12, 2025 | Sale | −24,300 | $1.99 | $48.36K | 1,813,439 |
| Nicholas A. Saccomano President and CEO, Director | Apr 7, 2025 | Sale | −516 | $2.67 | $1.38K | 3,682 |
| Jason A. Leverone Chief Financial Officer | Apr 7, 2025 | Sale | −1,844 | $2.67 | $4.92K | 13,209 |
| Nicholas A. Saccomano President and CEO, Director | Apr 4, 2025 | Sale | −358 | $3.33 | $1.19K | 4,198 |
| Jason A. Leverone Chief Financial Officer | Apr 4, 2025 | Sale | −1,278 | $3.33 | $4.26K | 15,053 |
| Isaac Manke Director | Mar 31, 2025 | Award | +3,469 | – | – | 3,469 |
| Edward T. Mathers Director | Mar 31, 2025 | Award | +2,580 | – | – | 2,580 |
| Braden Michael Leonard – | Oct 7, 2024 | Other | +345,739 | – | – | 345,739 |
| Braden Michael Leonard – | Oct 7, 2024 | Other | +102,076 | – | – | 102,076 |
| Jason A. Leverone Chief Financial Officer | Oct 4, 2024 | Award | +16,331 | – | – | 16,331 |
| Nicholas A. Saccomano President and CEO, Director | Oct 4, 2024 | Award | +4,556 | – | – | 4,556 |
| R. Michael Carruthers Director | Oct 4, 2024 | Award | +874 | – | – | 874 |
| R. Michael Carruthers Director | Oct 4, 2024 | Award | +4,065 | – | – | 4,939 |
| Braden Michael Leonard 10% owner | Sep 25, 2024 | Buy | +68,746 | $1.50 | $103.12K | 3,457,395 |
| Braden Michael Leonard 10% owner | Sep 24, 2024 | Buy | +29,600 | $1.41 | $41.74K | 3,388,649 |
| Braden Michael Leonard 10% owner | Sep 18, 2024 | Buy | +806 | $1.40 | $1.13K | 3,359,049 |
| Braden Michael Leonard 10% owner | Sep 17, 2024 | Buy | +55,300 | $1.36 | $75.21K | 3,358,243 |
| Braden Michael Leonard 10% owner | Sep 16, 2024 | Buy | +172,747 | $1.37 | $236.66K | 3,302,943 |
| Braden Michael Leonard 10% owner | Sep 13, 2024 | Buy | +150,000 | $1.31 | $196.50K | 3,130,196 |
| Braden Michael Leonard 10% owner | Sep 12, 2024 | Buy | +36,176 | $1.40 | $50.65K | 2,980,196 |
| Braden Michael Leonard 10% owner | Aug 14, 2024 | Buy | +100,487 | $1.41 | $141.69K | 2,944,020 |
| Braden Michael Leonard 10% owner | Aug 13, 2024 | Buy | +171,339 | $1.39 | $238.16K | 2,843,533 |
| Braden Michael Leonard 10% owner | May 14, 2024 | Buy | +335,000 | $1.54 | $515.90K | 2,672,194 |
| Braden Michael Leonard 10% owner | May 14, 2024 | Buy | +79,281 | $1.56 | $123.68K | 2,337,194 |
| Ashley Hall Chief Development Officer | Aug 28, 2023 | Option exercise | +15,625 | $1.80 | $28.13K | 55,225 |
| Ashley Hall Chief Development Officer | Aug 28, 2023 | Sale | −15,625 | $6.28 | $98.13K | 39,600 |
| Michael G. Grey Executive Chairman, Director | Jul 26, 2023 | Gift | −50,000 | – | – | 0 |
| Holdings A/S Novo 10% owner | Jun 23, 2023 | Sale | −100,000 | $7.10 | $710.00K | 3,330,337 |
| Niall O'Donnell Director | May 8, 2023 | Buy | +125,000 | $8.00 | $1.00M | 2,188,713 |
| Michael Cruse Chief Operating Officer | Sep 1, 2022 | Buy | +7,500 | $3.39 | $25.43K | 13,697 |
| Michael G. Grey Executive Chairman, Director | Aug 31, 2022 | Option exercise | +50,000 | $1.97 | $98.50K | 50,000 |
| Michael Cruse Chief Operating Officer | Aug 31, 2022 | Buy | +3,212 | $3.21 | $10.31K | 6,197 |
| Michael Cruse Chief Operating Officer | Aug 30, 2022 | Buy | +1,845 | $3.19 | $5.89K | 2,985 |
| Michael Cruse Chief Operating Officer | Aug 30, 2022 | Buy | +975 | $3.16 | $3.08K | 31,758 |
| Michael Cruse Chief Operating Officer | Aug 29, 2022 | Buy | +1,140 | $3.24 | $3.69K | 1,140 |
| Michael Cruse Chief Operating Officer | Aug 29, 2022 | Buy | +83 | $3.24 | $269 | 30,783 |
| Alejandro Dorenbaum Chief Medical Officer | Aug 12, 2022 | Gift | −22,348 | – | – | 30,000 |
| Alejandro Dorenbaum Chief Medical Officer | Dec 10, 2021 | Award | +30,000 | – | – | 52,348 |
| Michael Cruse Senior VP-Corporate Operations | Dec 10, 2021 | Award | +25,000 | – | – | 29,100 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of OnKure Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,960 shares on Sep 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Hall Ashley Officer | Aug 28, 2023 | 15,625 | $98.06K | Aug 28, 2023 | STOCK OPTION EXERCISE |
| Novo Holdings A/S 10% Stockholder | Jun 23, 2023 | 100,000 | $735.00K | Jun 23, 2023 | Purchase of stock in the Issuer's IPO |
See a number that looks wrong?